DISHMAN

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the meeting of the BOD's held on May 24, 2005, 1) the Board has recommended the final dividend @25% on the paid-up equity share capital of the Company, for the FY 2004-05; 2) resolution in respect of the re-appointment of Mr. Rajnikant T Vyas as Chairman & Managing Director of the Company and payment of remuneration to him has been passed, subject to approval of the Members in General Meeting, for a further period of five years w.e.f. July 01, 2005. The present term of appointment of Mr. Rajnikant T Vyas expires on

Dishman Pharmaceuticals And Chemicals Limited has submittted to the Exchange a copy of the notice of EGM of the members of the Company to be held on June 03, 2005. The details of the EGM notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the Board meeting held on May 08, 2005, the Board has decided to issue unsecured Foreign Currency Convertible Bonds (FCCBs) up to USD 50 Million with a right to retain the over subscription up to 20% of the FCCB issue with a authority to the Managing Director Mr. J. R. Vyas to appoint Book Runners and to negotiate and finalize the term sheet and to sign and execute the necessary documents and he is also authorized to do such other acts, deeds, matters and things as required and necessary in this regard. The Board h

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange regarding execution of various agreements with Arab Company for Drug Industries and Medical Appliances (ACDIMA) for setting up a joint venture project initially to manufacture 20 APIs for not only marketing in the Arab world but also exporting them. These Agreements were executed after discussions in India with senior level delegation consisting of Technical Director, ACDIMA, and Asst. Managing Director, Capital Advisory Group. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: C

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Company has acquired a Manchester U.K. based Contract Research Company, M/s Synprotec Ltd., through its 100% wholly owned U.K. based subsidiary company M/s Dishman Europe Ltd.. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the board meeting held on March 11,2005 the board approves strategic acquisition of a U.K. based Contract Research Company through its 100% wholly owned subsidiary(WOS) company namely Dishman Europe Ltd., with the authority to the Managing Director Mr.J.R.Vyas to negotiate and finalize the terms of acquisition and execute the necessary documents in this regard.This acquisition will strengthen the business model of Dishman Group.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the meeting of BODs of the company held on January 28, 2005, the resignation of Mr. Henk Pluim, has been accepted and he is ceased to be a Director of the company w.e.f January 28,2005.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the meeting of the BOD held on October 28, 2004, the Audit Committee, Remuneration Committee and Shareholders' & Investors' Grievance Committee of the Company, as earlier constituted, have been reconstituted by revision in the composition of members of all the three Committees. The details are as follows : 1) Audit Committee is re-constituted comprising of the following Directors : (i) Mr. Y B Desai, Chairman of the Audit Committee; (ii) Mr. Sanjay Majmudar; (iii) Mr. Ashok C Gandhi; (iv) Mr. Divyabhash C Anjaria.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the meeting of the BOD of the company held on October 28, 2004, Mr. D C Anjaria was appointed as an Additional Director of the Company with immediate effect.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that the Company has made an application on October 21, 2004 [in prescribed form 25-A of the Companies (Central Government's) general rules and forms, 1956] for the re-appointment of a Managing Director of the company for a further period of 5 years whose existing tenure expires on 28/02/2005. The application is also meant for payment of renumeration to him. The whole procedure as per the provisions of the Companies Act, was followed for making this application.

Dishman Pharmaceuticals And Chemicals Limited has informed the Exchange that at the AGM of the shareholders of the company held on September 24, 2004, the resolution for the reappointment of the retiring director namely, Dr. Klaas Zijlstra, as a Director of the company was unanimously voted against. Thus Dr. Klaas Zijlstra ceases to be a Director w.e.f. September 24, 2004. The Company has further informed the Exchange that in the said AGM, the shareholders have declared the final dividend @20% (Rs.2/- per equity share of Rs.10/- each) on the paid up equity share capital of Rs.1373.35 lacs for